Agios Pharmaceuticals (FRA:8AP) Debt-to-Asset : 0.03 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8AP Agios Pharmaceuticals Inc FRA:8AP
46 GF Score
Price €28.20
GF Value €102.82
! 3 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals Debt-to-Asset?

Agios Pharmaceuticals FRA:8AP -3.42% 46 Debt-to-Asset is 0.03 as of Jun. 2026. GuruFocus rates FRA:8AP with a GF Score™ of 46/100 and a GF Value™ of €102.82. The stock has 3 warning signs investors should review.

Agios Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €16.69 Mil. Agios Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €10.37 Mil. Agios Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was €962.11 Mil. Agios Pharmaceuticals's debt to asset for the quarter that ended in Jun. 2026 was 0.03.

Agios Pharmaceuticals  (FRA:8AP) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Agios Pharmaceuticals Debt-to-Asset Related Terms

Agios Pharmaceuticals Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Agios Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agios Pharmaceuticals Debt-to-Asset Chart

Agios Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.07 0.08 0.03 0.03

Agios Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.03 0.03 0.03

FRA:8AP vs GENB, ZYME, ZBIO: Debt-to-Asset Comparison

For the Biotechnology subindustry, Agios Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agios Pharmaceuticals Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Debt-to-Asset falls into.


FRA:8AP
46GF Score
Agios Pharmaceuticals Inc FRA:8AP
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Agios Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Agios Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(15.707 + 18.63) / 1107.83
=0.03

Agios Pharmaceuticals's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(16.687 + 10.369) / 962.112
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.03 mean?
Agios Pharmaceuticals (FRA:8AP) has a Debt-to-Asset of 0.03 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Agios Pharmaceuticals and its competitors.
Is Agios Pharmaceuticals' Debt-to-Asset too high?
Agios Pharmaceuticals' current Debt-to-Asset is 0.03. Overall, Agios Pharmaceuticals has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Debt-to-Asset compare to GENB and ZYME?
Agios Pharmaceuticals' Debt-to-Asset of 0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Agios Pharmaceuticals and its competitors. Agios Pharmaceuticals's current Debt-to-Asset is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Agios Pharmaceuticals (FRA:8AP) has a current Debt-to-Asset of 0.03. The stock's GF Value™ is €102.82, compared to a current price of €28.20 — trading 72.6% below its estimated fair value. The current Debt-to-Asset is 0.03. Agios Pharmaceuticals' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Agios Pharmaceuticals (FRA:8AP), the current Debt-to-Asset is 0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of €28.20 is trading 72.6% below its estimated GF Value™ of €102.82.

Key valuation signals for FRA:8AP:

  • Debt-to-Asset: 0.03
  • GF Value™: €102.82 vs. price of €28.20 (72.6% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agios Pharmaceuticals Business Description

Other Exchanges AGIO:USA0HB0:UK8AP:Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
46GF Score

Get the complete analysis for FRA:8AP

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.20
Price
€102.82
GF Value